Humana (HUM) Downgraded to Hold at ValuEngine

ValuEngine cut shares of Humana (NYSE:HUM) from a buy rating to a hold rating in a research report report published on Friday.

Several other equities analysts have also weighed in on the stock. Zacks Investment Research upgraded shares of Humana from a hold rating to a buy rating and set a $377.00 price objective on the stock in a report on Thursday, October 4th. Argus upped their target price on shares of Humana to $375.00 and gave the company a buy rating in a research note on Tuesday, September 4th. Piper Jaffray Companies upped their target price on shares of Humana from $355.00 to $380.00 and gave the company an overweight rating in a research note on Friday, August 24th. Barclays began coverage on shares of Humana in a research note on Thursday, September 13th. They issued an overweight rating and a $370.00 target price for the company. Finally, Royal Bank of Canada upped their target price on shares of Humana from $318.00 to $349.00 and gave the company a sector perform rating in a research note on Thursday, November 8th. Seven investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Humana presently has a consensus rating of Buy and an average price target of $352.10.

Shares of HUM stock traded down $10.27 during trading hours on Friday, reaching $306.00. 1,317,034 shares of the company were exchanged, compared to its average volume of 1,105,037. Humana has a fifty-two week low of $242.00 and a fifty-two week high of $355.88. The firm has a market capitalization of $43.39 billion, a price-to-earnings ratio of 26.13, a PEG ratio of 1.50 and a beta of 0.99. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.45.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.29 by $0.29. Humana had a net margin of 2.70% and a return on equity of 19.10%. The company had revenue of $14.21 billion for the quarter, compared to analyst estimates of $13.97 billion. During the same period in the prior year, the business earned $3.39 earnings per share. On average, equities research analysts forecast that Humana will post 14.43 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 25th. Stockholders of record on Monday, December 31st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 0.65%. The ex-dividend date of this dividend is Friday, December 28th. Humana’s dividend payout ratio is 11.96%.

In other news, insider Roy A. Beveridge sold 4,622 shares of the stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $341.06, for a total transaction of $1,576,379.32. Following the completion of the sale, the insider now owns 10,621 shares of the company’s stock, valued at $3,622,398.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bruce D. Broussard sold 18,000 shares of the firm’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the completion of the transaction, the chief executive officer now directly owns 71,085 shares of the company’s stock, valued at approximately $23,362,796.10. The disclosure for this sale can be found here. 0.60% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. FMR LLC grew its position in Humana by 1.4% in the third quarter. FMR LLC now owns 12,379,797 shares of the insurance provider’s stock valued at $4,190,809,000 after purchasing an additional 167,283 shares in the last quarter. BlackRock Inc. grew its position in Humana by 1.2% in the third quarter. BlackRock Inc. now owns 12,311,736 shares of the insurance provider’s stock valued at $4,167,767,000 after purchasing an additional 140,731 shares in the last quarter. Vanguard Group Inc. grew its position in Humana by 1.4% in the third quarter. Vanguard Group Inc. now owns 10,104,225 shares of the insurance provider’s stock valued at $3,420,482,000 after purchasing an additional 140,864 shares in the last quarter. Capital International Investors grew its position in Humana by 3,030.3% in the third quarter. Capital International Investors now owns 8,217,296 shares of the insurance provider’s stock valued at $2,781,719,000 after purchasing an additional 7,954,786 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Humana by 14.1% in the third quarter. Renaissance Technologies LLC now owns 3,174,800 shares of the insurance provider’s stock valued at $1,074,733,000 after purchasing an additional 391,300 shares in the last quarter. 92.90% of the stock is owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Recommended Story: What are the most popular ETFs

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply